By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Amid recent backlash stemming from market withdrawals and trial delays, the FDA seeks to further clarify its requirements for ...

BioSpace presents 25 noteworthy biopharma startups in ’25; analysts forecast stronger M&A as the J.P. Morgan Healthcare Conference kicks off next week; GLP-1s continue to expand their reach as Novo, ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.